Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
COSCIENS Biopharma ( (TSE:CSCI) ) has issued an announcement.
On May 12, 2026, COSCIENS Biopharma filed a Form 6-K for May 2026, furnishing unaudited condensed interim consolidated financial statements and management’s discussion and analysis for the quarter ended March 31, 2026. The filing also included officer certifications, reinforcing the company’s adherence to Canadian securities requirements and its ongoing reporting role as a foreign private issuer.
The Q1 2026 balance sheet shows total assets of $18.8 million and a sharp reduction in total liabilities to $3.5 million from $17.6 million at year-end 2025, driving shareholders’ equity up to $15.3 million from $3.8 million. The company reported net profit of $10.8 million for the quarter, reversing a prior accumulated deficit, while warning that forward-looking statements are subject to significant risks and uncertainties highlighted in its previously filed risk disclosures.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a biopharmaceutical company focused on developing and commercializing therapies, operating as a foreign private issuer with its primary listing in Canada and reporting obligations in both Canadian and U.S. markets. The company’s activities are reflected in its condensed interim consolidated financial statements prepared in U.S. dollars, underscoring its cross-border capital markets presence.
Average Trading Volume: 4,366
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$8.25M
Learn more about CSCI stock on TipRanks’ Stock Analysis page.